The purpose of this study is to compare the effects of Lisinopril or Coreg, compared to placebo for the ability to reduce the incidence of Trastuzumab-induced cardiotoxicity. The subject must be a female and greater than 18 years old who is being treated for HER2 positive breast breast cancer which has recurred locally or spread to other parts of the body. This study will tell us which treatment (Lisinopril or Coreg CR), if any, is better at protecting heart function during treatment of breast cancer with Trastuzumab. Three groups of patients will be analyzed: patients who receive Lisinopril, patients who receive Coreg and those that receive placebo only.
SCUSF 0806: Phase II, Placebo-Controlled Trial of Lisinopril and Coreg CR® to Reduce Cardiotoxicity in Patients with Breast Cancer Receiving (Neo)adjuvant Chemotherapy with Trastuzumab (Herceptin®)
010-11Principal Investigator: Conducted at:
Long Beach MemorialCurrently enrolling additional patients:
18 & olderGender: